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Purpose. To evaluate the ability of new swept-source (SS) optical coherence tomography (OCT) technology to detect changes in
retinal and choroidal thickness in patients with multiple sclerosis (MS).Methods. A total of 101 healthy and 97MS eyes underwent
retinal and choroidal assessment using SS Triton OCT (Topcon). Macular thickness and peripapillary data (retinal, ganglion cell
layer (GCL+, GCL++) and retinal nerve fiber layer (RNFL) thickness) were analyzed, including choroidal thickness evaluation.
Results. Significant macular thinning was observed in all ETDRS areas (p< 0.001) in MS patients. Peripapillary retinal, RNFL, and
GCL ++ thickness showed a significant reduction in patients in all sectors (p< 0.001) except in the nasal quadrant/sector
(p> 0.05). GCL+ measurements were found to be reduced in the nasal (p  0.003), inferonasal (p  0.045), and temporal
(p  0.001) sectors and total thickness (p< 0.001). Choroidal thickness was reduced in the outer macular ring in MS patients
compared with controls (p  0.038). Conclusion. New swept-source technology for OCT devices detects retinal thinning in MS
patients, providing increased depth analysis of the choroid in these patients. MS patients present reduced retinal and choroidal
thickness in the macular area and reduced peripapillary retinal, RNFL, and GCL thickness.
1. Introduction
Optic nerve atrophy and thinning of the peripapillary retinal
nerve fiber layer (RNFL) are two typical findings of patients
with multiple sclerosis (MS). Axonal damage already occurs
in the early stages of the disease, and its relationship with
demyelination is still unclear [1, 2]. Axonal damage is con-
sidered to be the main cause of disability in MS [3–5] and can
be detected and quantified at the level of the retinal nerve fiber
layer (RNFL) using ocular imaging technologies, such as
optical coherence tomography (OCT) [5–10]. So far, studies
using spectral-domain OCT have revealed that the retina in
nonoptic neuritis (non-ON) eyes shows thinner peripapillary
RNFL (pRNFL) than healthy controls [4, 11–13].
Digital imaging technologies in ophthalmology have
greatly improved in the recent years. The most recent
milestone in the development of retina and choroid
structural visualization strategies is swept-source (SS)
OCT, which overcomes the scattering of light on the
choroid thanks to longer wavelengths than those used in
SD systems (1,050 nm vs 840 nm) [14]. The scan speed in
SS-OCT devices is of 100,000A scans/sec, providing more
accurate three-dimensional images of the retina and
choroid [14, 15].
In the present study, we evaluated retinal and choroidal
thickness in patients with MS without previous ON episodes
(that is, without acute loss of RNFL thickness), using new SS-
deep range imaging (DRI) OCT technology and compared
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obtained measurements with a group of healthy subjects. To
the best of our knowledge, this is the first study evaluating
MS eyes using new SS-DRI OCT technology.
2. Methods
All procedures in this study adhered to the tenets of the
Declaration of Helsinki; the experimental protocol was
approved by the Ethics Committee of the Miguel Servet
Hospital (CEICA), and all participants provided written
informed consent to participate in the study.
Patients with definite relapsing-remitting (RR) MS were
included in an observational cross-sectional study. The
sample size was calculated in order to detect significant
differences in the RNFL, assuming an α error of 5% and a β
error of 10%. Based on these calculations, the number of
subjects needed was at least 80. A total of 97 eyes of 97
patients and 100 eyes of 100 healthy individuals were
evaluated.
The diagnosis of MS was based on the McDonald criteria
[16] and confirmed by a neurologist. Relatedmedical records
(neurological and ophthalmological) were carefully evalu-
ated, and information about Expanded Disability Status
Scale (EDSS) scores, disease duration and subtype, modi-
fying disease treatments, and prior episodes ON (based on
the standardized definition of ON using clinical criteria [17])
were recorded. Only patients with relapsing-remitting MS
were included in our study. Patients with visual acuity <0.1
(6/60, using the Snellen chart) and intraocular pressure
>20mmHg and/or active MS outbreaks (of any neurologic
deficit) in the 6 months preceding enrollment in the study
were excluded from the study. The reason to exclude active
neurological flare ups was that acute axonal losses did not
mask neuronal damage secondary to MS progression
(i.e., chronic neurodegeneration). Patients with previous ON
history were excluded from the study because we aimed at
evaluating the ability of Triton OCT to detect subclinical
axonal damage in the RNFL of these patients compared to
controls. Axial length was assessed in all individuals. Eyes
longer than 25.2mm and refractive errors ≥5 diopters (D) of
spherical equivalent or ≥3D of astigmatism were excluded
from the study.
Structural measurements of the retina were obtained
using the DRI Triton SS-OCTdevice (Topcon, Tokyo, Japan)
which uses a tunable laser as a light source to provide
a 1050 nm centered wavelength. This device reaches
a scanning speed of 100,000 A-scans per second, yielding 8
and 20 μm axial and transverse resolution in tissue, re-
spectively. The 3D wide protocol was used for all subjects.
This protocol includes a wide scanning range that focuses
both in the macular (ETDRS scan) and the peripapillary area
(TSNIT). The diameter of the peripapillary area measured
with this protocol is 3.40mm. With the ETDRS scan nine
macular areas [18] (which include a central 1mm circle
representing the fovea, and inner and outer rings measuring
3mm and 6mm in diameter, respectively), central and
average thickness plus macular volume are analyzed; the
TSNIT scan provides automated separate measurements of
different retinal layers: retinal nerve fiber layer (RNFL)
(between the inner limiting membrane (ILM)to the GCL
boundaries), ganglion cell layer (GCL) + (between RNFL to
the inner nuclear layer boundaries), GCL++ (between ILM
to the inner nuclear layer boundaries), and retinal thickness
(from the ILM to the retinal pigment epithelium bound-
aries). The TSNIT provides measurements of the 4 peri-
papillary quadrants (superior, nasal, inferior, and temporal),
6 sectors (superonasal, superotemporal, nasal, temporal,
inferonasal, and inferotemporal), and 12 clock sectors.
Additionally, both EDTRS and TSNIT protocols provide
automated choroidal thickness measurements (from the
Bruch membrane to the choroidal-scleral interface,
Figure 1).
In this study, we followed the methods of Satue et al.
2017 [19]. Macular (ETDRS, GCL+, and GCL++) and
peripapillary (RNFL, GCL+, and GCL++) thickness were
evaluated. Choroidal measurements were obtained for both
the macular (ETDRS) and peripapillary area (TSNIT).
All variables were registered in a database created with
Excel 2010 (Microsoft Corporation). Modifier variables were
age, sex, intraocular pressure, and axial length. Statistical
analysis was performed using commercial predictive ana-
lytics software (SPSS, version 20.0; SPSS, Inc., Chicago, IL).
The normality of the sample distribution was confirmed
using the Kolmogorov–Smirnov test (p> 0.05). Bonferroni
correction for multiple comparisons was applied. Com-
parisons between patients and controls were calculated using
Student’s t test. p value ≤0.05 was considered of statistical
significance. Results of calculations are reported as “mean”
and “standard deviation.” Only one eye per patient was
randomly selected for the study.
3. Results
Ninety-seven eyes of 97 RR MS patients with a mean age of
48.46 years (SD  11.31) and 101 eyes of 101 healthy in-
dividuals with a mean age of 47.58 years (SD  9.37) were
included in the study.Themale/female ratio was 1/11 in the
MS group (8/89) and 1/10 in the control group (9/91).
Mean axial length was 23.52 ± 0.6mm in the control group,
and 23.60 ± 0.2mm in the MS group. Mean age, sex, in-
traocular pressure, and axial length did not differ
significantly between the groups (p  0.610, 0.659,
0.865, and 0.522, respectively). Mean disease duration in
the group of patients was 7.56 years (SD  2.66). The
median EDSS score was 1.50 (interquartile range (IQR) 
2.30), and all patients suffered from relapsing-remitting MS
subtype. No previous acute optic neuritis attack was re-
ported in any of our patients.
Measurements obtained with SS DRI Triton OCT
showed reduced retinal thickness in all macular ETDRS
sectors in MS patients compared with controls (p< 0.001).
Macular volume was also significantly reduced in patients
(7.92mm3 in controls vs 7.54mm3 in patients, p< 0.001).
Results can be observed in Table 1.
Significant peripapillary retinal and RNFL thinning was
observed in all measured areas (total thickness, quadrants,
and sectors, p< 0.001) except in the nasal quadrant/sector
(Table 2).
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The ganglion cell layer as measured from the RNFL to
the boundaries of the inner nuclear layer (GCL+) was
found to be reduced in the nasal (40.96 μm in controls vs
38.96 μm in patients, p  0.003) and temporal (52.31 μm vs
49.20 μm, p  0.001) quadrants, in the nasal (40.96 μm vs
38.96 μm, p  0.003), inferonasal (37.51 μm vs 35.57 μm,
p  0.045), and temporal (52.31 μm vs 49.20 μm, p  0.001)
sectors, and in total thickness (43.20 μm vs 41.21 μm,
p< 0.001) (Table 2).
Automated measurements of the macular and peri-
papillary choroidal thickness in MS patients did not show
any significant differences compared with healthy con-
trols. However, a clear tendency toward reduced choroidal
thickness was observed in the peripapillary area (Table 3).
This tendency was not observed in the ETDRS macular
choroidal measurements (Supplementary Table 1). A
secondary analysis of the ETDRS choroidal thickness was
performed due to high standard deviation values. The four
areas of the 3mm inner ETDRS ring (superior, nasal,
inferior, and temporal) were assembled and calculated as
only one area (inner ring), and the four areas of the 6mm
outer ETDRS ring (superior, nasal, inferior and tempo-
ral) were calculated as other unique area (outer ring).
The outer ring of the choroidal plexus was found to be
significantly reduced in MS patients compared with
controls (261.41 μm in controls vs 254.46 μm in patients,
p  0.038).
Figure 1: Segmentation of the choroidal plexus of the peripapillary area. Automated segmentation of the peripapillary choroidal plexus and
analyzed data provided by Triton OCT in a patient with multiple sclerosis. Arrows indicate the boundaries of the choroidal plexus.
Table 1: Macular retinal thickness and macular volume as mea-
sured with swept-source deep range imaging optical coherence
tomography Triton in patients with multiple sclerosis and healthy
subjects.
Macular thickness Healthycontrols MS p
Center (μm) 255.38 (35.19) 230.49(14.54) <0.001
∗
Inner superior (μm) 320.93 (17.13) 297.08(19.87) <0.001
∗
Inner nasal (μm) 323.30 (16.00) 298.93(13.49) <0.001
∗
Inner inferior (μm) 318.41 (13.19) 296.88(13.77) <0.001
∗
Inner temporal (μm) 306.10 (20.33) 286.54(12.84) <0.001
∗
Outer superior (μm) 272.51 (13.87) 263.92 (9.76) <0.001∗
Outer nasal (μm) 290.52 (14.84) 274.56(13.85) <0.001
∗
Outer inferior (μm) 263.01 (15.75) 252.94(12.83) <0.001
∗
Outer temporal (μm) 255.21 (18.31) 248.72 (9.60) <0.001∗
Average thickness
(μm) 280.41 (13.97) 266.95 (9.83) <0.001
∗
Volume (mm3) 7.92 (0.39) 7.54 (0.27) <0.001∗
Numbers indicate mean values with standard deviation between
brackets. Bold letters indicate statistical significance. ∗Significant values
after Bonferroni correction for multiple comparisons; MS, multiple
sclerosis.
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4. Discussion
In the present study, we evaluated retinal and choroidal
changes in MS patients using new SS DRI Triton OCTdevice.
To the best of our knowledge, this is the first study assessing
the ability of Swept-source OCT technology to detect retinal
changes in MS. Triton SS-OCT analyzed retinal thickness in
both the macular and peripapillary area and also two other
retinal layers: RNFL and GCL + (both in the peripapillary
area). Triton SS-OCTdetected significant retinal thinning in all
the ETDRS areas in our patients, as well as retinal and RNFL
thinning in all sectors of the peripapillary measurements
(except in the nasal quadrant/sector). Surprisingly, ganglion
cell layer measurements (GCL+) only showed significant re-
duction in the nasal and temporal quadrants/sectors.
Previous studies using SD-OCT segmentation analysis
software demonstrated a reduction of the macular inner
retinal layers, including the GCL + IPL, in patients with MS,
suggesting ganglion cell loss [20–23]. Recent research
demonstrated that GCL measurements as obtained with SD-
OCTdevices may be a better marker for axonal degeneration
in MS compared with RNFL thickness [23]. In a recent study
comparing both macular GCL + IPL and peripapillary RNFL
thickness, average GCL + IPL was altered more frequently
than average peripapillary RNFL, and GCL + IPL thickness
demonstrated to have better sensitivity than temporal
peripapillary RNFL thickness for detecting retinal thickness
changes in patients with MS [12, 24]. Our study did not
include macular GCL + thickness. However, in our patients,
peripapillary RNFL thickness was altered more frequently
Table 2: Peripapillary retinal and ganglion cell layer thickness as measured with swept-source deep range imaging optical coherence
tomography Triton in patients with multiple sclerosis and healthy subjects.
Peripapillary measurements Healthy controls MS p
Retinal thickness
Total 291.87 (15.32) 277.75 (16.86) <0.001∗
Quadrants (x4)
Superior 310.03 (21.53) 292.81 (24.05) <0.001∗
Nasal 262.33 (16.02) 259.02 (14.72) 0.129
Inferior 313.45 (21.19) 292.03 (21.51) <0.001∗
Temporal 281.53 (12.80) 267.10 (16.70) <0.001∗
Sectors (x6)
Superonasal 302.64 (27.51) 284.88 (27.06) <0.001∗
Superotemporal 321.31 (20.46) 303.05 (25.56) <0.001∗
Nasal 267.47 (16.33) 262.17 (14.60) 0.016
Inferonasal 310.43 (26.81) 289.10 (27.09) <0.001∗
Inferotemporal 323.19 (21.25) 300.61 (23.25) <0.001∗
Temporal 281.53 (12.80) 267.10 (16.70) <0.001∗
RNFL thickness
Total 104.74 (11.38) 94.60 (14.40) <0.001∗
Quadrants (x4)
Superior 126.03 (18.03) 112.39 (19.36) <0.001∗
Nasal 76.51 (11.02) 78.97 (14.04) 0.166
Inferior 139.40 (19.71) 120.23 (20.99) <0.001∗
Temporal 76.93 (12.43) 66.79 (16.64) <0.001∗
Sectors (x6)
Superonasal 117.01 (25.30) 101.49 (21.42) <0.001∗
Superotemporal 138.00 (18.35) 124.48 (24.93) <0.001∗
Nasal 83.12 (12.00) 83.25 (14.12) 0.966
Inferonasal 138.63 (27.54) 119.83 (28.49) <0.001∗
Inferotemporal 147.17 (22.60) 126.31 (26.18) <0.001∗
Temporal 76.93 (12.43) 66.79 (16.64) <0.001∗
GCL + thickness
Total 43.20 (4.06) 41.21 (3.60) <0.001∗
Quadrants (x4)
Superior 40.72 (5.39) 39.49 (4.29) 0.076
Nasal 40.96 (4.36) 38.96 (5.15) 0.003
Inferior 38.81 (5.39) 37.16 (5.73) 0.036
Temporal 52.31 (7.02) 49.20 (6.03) 0.001∗
Sectors (x6)
Superonasal 41.94 (6.29) 41.37 (4.93) 0.481
Superotemporal 39.98 (7.54) 38.29 (6.01) 0.083
Nasal 40.46 (4.32) 38.53 (4.80) 0.003
Inferonasal 37.51 (6.36) 35.57 (7.29) 0.045
Inferotemporal 40.39 (7.03) 38.91 (7.10) 0.139
Temporal 52.31 (7.02) 49.20 (6.03) 0.001∗
Numbers indicate mean values with standard deviation between brackets. Bold letters indicate statistical significance. ∗Significant values after Bonferroni
correction for multiple comparisons; MS, multiple sclerosis; RNFL, retinal nerve fiber layer; GCL, ganglion cell layer.
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than peripapillary GCL measurements (GCL+), and the
latter were more reduced in temporal and nasal areas. The
fact that the nasal quadrant is affected only in the GCL + in
our patients (and not in the RNFL, GCL++) may suggest
that, indeed, GCL measurements are somewhat a more
subtle marker for neurodegeneration than RNFL thickness.
However, more studies with SS-OCT technology including
macular GCL + measurements are needed to corroborate
these findings.
The choroid (present both in the ocular globe and the
central nervous system) is composed of epithelial cells
resting on a basal lamina. These epithelial cells produce the
cerebrospinal fluid, which has many functions, such as
providing mechanical support, a route for some nutrients
and removing by-products of metabolism and synaptic
activity [25]. The tight junctions located in the choroidal
epithelial cells of the central nervous system form the blood-
cerebrospinal fluid barrier. Previous atrophy of the
choroidal epithelial cells and thickening of the basement
membrane were observed in the central nervous system’s
choroidal plexus of patients with other neurodegenerative
diseases, such as Alzheimer’s disease [25]. In MS, an in-
flammatory disease, pathogenic autoreactive T lymphocytes
may migrate through the blood-cerebrospinal fluid barrier
of the choroid into the central nervous system [25]. Few
previous studies focused on ocular choroidal thickness
measurements in MS using OCT imaging, and none of them
included SS technology. Esen et al. demonstrated, using
enhanced depth imaging (EDI) SD OCT, that the subfoveal
choroidal plexus in these patients was significantly reduced
compared with healthy individuals, and this reduction was
associated with disease duration [26]. Our patients showed
significant reduced choroidal thickness in the assembled
outer ring of the macular area, but not when the 9 separate
EDTRS areas were compared. Additionally, the peripapillary
choroidal plexus seemed to be diminished in our patients
compared with controls (although this finding was not
significant). Choroidal thickness is influenced by the axial
length of the eye. Both refractive errors and axial length were
evaluated in our study and did not differ significantly be-
tween patients and controls. Recent research comparing SD-
OCT and SS-OCT choroidal measurements in healthy and
high myopic subjects demonstrated that SS-OCT mea-
surements provide better quality of choroidal images, which
allows higher rates of measurement of this layer [15, 27].
However, choroidal measurements in our study were au-
tomatically obtained, which could add segmentation arte-
facts, but also decrease bias induced by manual
measurement. In our opinion, more studies comparing SD-
OCT and SS-OCT choroidal measurements in MS patients
are needed to corroborate our findings.
A possible limitation is that subclinical glaucomatous
eyes might have been included in the study, despite all
participants (MS and controls) being evaluated for IOP
levels (but not for glaucomatous changes in perimetry). It is
possible that both the patient and the control group of
subjects contained subclinical glaucomatous eyes. However,
since this would have randomly affected both comparative
groups, we do not consider this to alter significantly the
results of our study. Another possible limitation is that the
quality of some of the scans would have caused the choroidal
thickness in the MS to be diminished when automated
segmentation was applied. Nevertheless, we checked the
quality of the scans immediately after acquisition, all quality
scores were >55 in both groups, and no statistical difference
between the MS and the control group was observed
(p> 0.05)
5. Conclusions
New swept-source technology for OCT devices detects
macular thinning and peripapillary retinal, RNFL, and GCL
reduction in MS patients, providing increased and more
detailed evaluation of the choroid in these patients. Based on
our findings, SS-OCTdevices could be used as an alternative
tool to SD-technology in the routine evaluation of patients
with MS. Moreover, since SS-OCTprovides increased depth
Table 3: Macular and peripapillary choroidal thickness as mea-
sured with swept-source deep range imaging optical coherence





































Temporal 175.93 (97.12) 174.20(93.97) 0.898
All measurements are in microns. Each of the four macular areas in the
3mm and 6mm ring of the ETDRS are assembled into one unique inner
and outer ring, due to elevated standard deviation. Bold letters indicate
statistical significance. MS, multiple sclerosis.
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analysis of the choroid in these patients, analyzing the ocular
choroidal plexus in MS subjects could add valuable in-
formation on the possible affectation of the ocular layers and
reflect degeneration in other central nervous system
structures. However, similar studies comparing new swept-
source and SD OCT technology for the evaluation of MS
would still be needed to corroborate our findings.
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